BioSpace News Archive

Disc Medicine, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DISC-3405 for the treatment of patients with polycythemia vera (PV).

Lineage Cell Therapeutics, Inc. today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company’s common shares at an offering price of $1.04 per common share.

Iambic Therapeutics announced the appointment of oncologist and industry veteran Neil Josephson, M.D., as its Chief Medical Officer.

Gilead Sciences, Inc. announced the company has been named one of America’s Most JUST Companies.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled Phase 2/3 study (SCORPIO-SR) in patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam in JAMA Network Open.

Amgen will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024.

Leading nonprofit, integrated health care organization maintains focus on its mission while navigating a dynamic health care environment.

Mirum Pharmaceuticals, Inc. announced that on February 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 33,200 shares of common stock and 16,610 restricted stock units to seven new employees under Mirum’s 2020 Inducement Plan.

Sensorion announced a €50.5 million offering reserved to specific categories of investors through the issuance of 88,594,737 new ordinary shares of the Company at a price per New Share of €0.57 to the benefit of Redmile Group, Invus and Sofinnova Partners, existing shareholders, and leading US Healthcare Specialists funds including Aquilo Capital, as well as two large investment management firms.

Senzime Senzime invites investors, analysts, and media to a webcast presentation of the fourth quarter report for 2023 on February 15, 08:30 CET.